TLR7/9 Antagonist Reduces HIV-1-Induced Immune Activation by Lindsay, RJ et al.
 
TLR7/9 Antagonist Reduces HIV-1-Induced Immune Activation
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Chang, J., R. J. Lindsay, E. H. Doyle, V. Vrbanac, E. N. Seung,
T. Dudek, R. J. Bosch, M. Precopio, E. Kandimalla, A. Tager,
and M. Altfeld. 2012. TLR7/9 antagonist reduces HIV-1-
induced immune activation. Poster Presentation. Retrovirology
9(Suppl 2): P172.
Published Version doi:10.1186/1742-4690-9-S2-P172
Accessed February 19, 2015 10:49:42 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10536954
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAPOSTER PRESENTATION Open Access
TLR7/9 antagonist reduces HIV-1-induced
immune activation
J Chang
1*, RJ Lindsay
1, EH Doyle
1, V Vrbanac
2, EN Seung
2, T Dudek
1, RJ Bosch
3, M Precopio
4, E Kandimalla
4,
A Tager
2, M Altfeld
1
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
T cell immune activation is a strong predictor of HIV-1
disease progression and HIV-1 transmission, and IFN-
alpha production following TLR7 stimulation has been
associated with elevated CD8
+ T cell activation (Meier
et al., Nat Med 2009). We therefore hypothesized that
modulation of TLR7 stimulation could be used to manipu-
late IFN-alpha production and subsequently reduce HIV-
1-associated immune activation. TLR7/9-specific antago-
nists developed for treatment of auto-immune diseases
were used in vitro and in vivo in a humanized mouse
model.
Methods
Humanized BLT mice were generated by transplanting
irradiated NOD/SCID/gc
-/- mice with human fetal thy-
mus and injected with human hematopoietic stem cells
isolated from matching liver tissue. Following reconstitu-
tion, cells were harvested from the mice to examine the
effects of the antagonist in vitro. Humanized mice were
also infected with HIV-1 and then either treated or
untreated with TLR7/9 antagonist from Idera. T cell acti-
vation markers were examined pre-infection, following
infection and during treatment with the antagonist. Addi-
tionally, responsiveness of DCs to TLR7/8 stimulation ex
vivo following in vivo TLR7/9 antagonist treatment was
assessed by intracellular cytokine staining.
Results
16-20 weeks after transplant, human DC, monocyte and
T cell populations were detectable in the mice. Ex vivo
stimulation with TLR7/8 induced cytokine production
by humanized mice DCs and monocytes similar to those
observed from human PBMCs and this was significantly
blocked by in vitro treatment with the TLR7/9 antago-
nist (P<0.05). HIV-1 infection of humanized mice led to
increased T cell immune activation marker CD38 on
human T cells in vivo, and treatment of infected mice
with the TLR7/9 antagonist led to a significant reduc-
tion in CD38 expression.
Conclusion
Treatment of HIV-1-infected humanized BLT mice with
a TLR7/9 antagonist resulted in a significant reduction
of HIV-1-associated immune activation. This may have
important implications in reducing viral transmission
associated with higher immune activation in HIV-1.
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